Vaccine developed for cervical cancer and genital warts: "Posted on 08 April 2005, � Asian News International
Vaccine developed for cervical cancer and genital warts
Health News, Washington: A new study published in the Lancet suggest that researchers at the Ludwig Institute for Cancer Research, Brazil have found a vaccine against the virus that causes cervical cancer and genital warts that could reduce persistent infection and disease by 90 percent.
The team led by Luisa Villa undertook a trial to test the effectiveness of a vaccine targeting the HPV types associated with 70 percent of cervical cancers (types 16 and 18) and 90 percent of genital warts (types 6 an 11). The investigators recruited 1158 healthy women aged 16-23 onto the study from Brazil, Europe and the USA.
The participants were not pregnant, had no previous abnormal cervical smears and reported a history of four or fewer partners. 277 women were randomly assigned to the vaccine and 275 to a placebo. They received given intramuscular injections on day 1, month 2 and month 6.
They were followed up for 36 months and underwent regular gynaecological examinations, sampling for HPV DNA and cervical smears. The incidence of persistent infection or disease with HPV 6, 11, 16, or 18 fell by 90percent in those assigned the vaccine compared with those assigned the placebo.
The vaccine was 100percent effective against precancerous cervical lesions and genital warts associated with these four HPV types. There were no vaccine related serious adverse events.
The authors suggest that universal HPV vaccination might be most effective if implemented in 10-13 year olds, who are likely to be HPV negative. Large-scale trials of the vaccine are currently underway. "
Vaccine developed for cervical cancer and genital warts
Health News, Washington: A new study published in the Lancet suggest that researchers at the Ludwig Institute for Cancer Research, Brazil have found a vaccine against the virus that causes cervical cancer and genital warts that could reduce persistent infection and disease by 90 percent.
The team led by Luisa Villa undertook a trial to test the effectiveness of a vaccine targeting the HPV types associated with 70 percent of cervical cancers (types 16 and 18) and 90 percent of genital warts (types 6 an 11). The investigators recruited 1158 healthy women aged 16-23 onto the study from Brazil, Europe and the USA.
The participants were not pregnant, had no previous abnormal cervical smears and reported a history of four or fewer partners. 277 women were randomly assigned to the vaccine and 275 to a placebo. They received given intramuscular injections on day 1, month 2 and month 6.
They were followed up for 36 months and underwent regular gynaecological examinations, sampling for HPV DNA and cervical smears. The incidence of persistent infection or disease with HPV 6, 11, 16, or 18 fell by 90percent in those assigned the vaccine compared with those assigned the placebo.
The vaccine was 100percent effective against precancerous cervical lesions and genital warts associated with these four HPV types. There were no vaccine related serious adverse events.
The authors suggest that universal HPV vaccination might be most effective if implemented in 10-13 year olds, who are likely to be HPV negative. Large-scale trials of the vaccine are currently underway. "
Comments